Denosumab — CPB 0804 | AETNA Coverage Update

TL;DR: Aetna modified CPB 0804 governing denosumab coverage policy, effective December 20, 2025. Billing teams using J0897, Q5136, Q5157, Q5158, or Q5159 need to review updated medical necessity criteria and biosimilar coverage before submitting claims.

Aetna's updated denosumab coverage policy under CPB 0804 now covers multiple biosimilar products alongside the reference drugs Prolia and Xgeva. The policy applies to commercial medical plans only — for Medicare, Aetna directs you to their Part B step therapy criteria. Precertification is required across all applicable plan designs. If your team bills denosumab injections under J0897 or any of the biosimilar Q-codes, this policy change affects your prior authorization workflow starting December 20, 2025.

---

Quick Reference

Field	Detail
Payer	Aetna
Policy	Denosumab — CPB 0804
Policy Code	CPB 0804
Change Type	Modified
Effective Date	December 20, 2025
Impact Level	High
Specialties Affected	Oncology, Rheumatology, Endocrinology, Orthopedics, Urology
Key Action	Update your prior auth workflow to include biosimilar Q-codes (Q5136, Q5157, Q5158, Q5159) and confirm medical necessity documentation before billing J0897 or biosimilar equivalents

---

Aetna Denosumab Coverage Criteria and Medical Necessity Requirements 2025

Aetna's denosumab coverage policy splits coverage into two product families. Prolia and its biosimilars (Jubbonti, Stoboclo, Conexxence, Ospomyv) cover osteoporosis indications. Xgeva and its biosimilars (Wyost, Osenvelt, Bomyntra, Xbryk) cover oncology indications — bone metastases, multiple myeloma, and giant cell tumor of bone.

The HCPCS code grouping under J0897 also includes denosumab-kyqq (Bosaya) and denosumab-nxxp (Bildyos). Review the full CPB 0804 policy text to confirm how these products map to your specific plan and billing scenarios.

The real issue here is the step therapy structure. Aetna doesn't just ask whether the diagnosis exists. It asks whether the member tried something else first — and failed. That distinction drives most claim denials on this drug.

Prolia and Biosimilars — Osteoporosis Indications

Postmenopausal osteoporosis qualifies for medical necessity under one of two paths. First, the member has a history of fragility fractures — low trauma fractures from a force similar to a fall from standing height. Second, the member has a pre-treatment T-score ≤ -2.5, or osteopenia (T-score between -2.5 and -1.0) with a high FRAX fracture probability, plus one of these additional factors:

#	Covered Indication Copy
1	Indicators of very high fracture risk: advanced age, frailty, glucocorticoid use, T-score ≤ -3, or increased fall risk
2	Prior failure or intolerance to injectable osteoporosis therapy (zoledronic acid, teriparatide, abaloparatide)
3	A completed oral bisphosphonate trial of at least one year, or a documented clinical reason to avoid oral bisphosphonates

That third bullet is where most denials originate. Your documentation needs to show the bisphosphonate trial actually happened — duration, drug, and outcome — or it needs a specific clinical reason on record for why the member couldn't take one.

Osteoporosis in men requires either a history of osteoporotic vertebral or hip fracture, or a T-score ≤ -2.5 (or osteopenia with high FRAX probability) combined with a one-year oral or injectable bisphosphonate trial, or documented clinical reasons to avoid bisphosphonates.

Glucocorticoid-induced osteoporosis requires all three of the following: current or planned glucocorticoid therapy at ≥ 2.5 mg/day prednisone equivalent for three or more months, a completed bisphosphonate trial of at least one year or a reason to avoid bisphosphonates, and either a fragility fracture history or a qualifying T-score.

Prior Authorization Requirements

Prior authorization is mandatory for all denosumab products across all applicable Aetna commercial plan designs. Call (866) 752-7021 or fax (888) 267-3277 to initiate precertification. Use Aetna's Specialty Pharmacy Precertification forms for Statement of Medical Necessity submissions. This applies equally to the reference drugs (J0897 for either Prolia or Xgeva dosing) and to all four biosimilar Q-codes.

Continuation and Renewal Criteria

CPB 0804 includes continuation and renewal criteria for Prolia. Review the full policy text at app.payerpolicy.org/p/aetna/0804 to confirm what ongoing documentation Aetna requires before your next renewal submission. Don't assume a prior auth that was approved once rolls over automatically.

---

Aetna Denosumab Exclusions and Non-Covered Indications

Several combinations and investigational uses are explicitly excluded from coverage under CPB 0804. The HCPCS code groupings in the policy data flag these directly.

Denosumab combined with other agents for specific cancer indications is not covered. The policy excludes denosumab combined with chemotherapy agents (J9000 doxorubicin, J9022 atezolizumab, J9228 ipilimumab, J9271 pembrolizumab, J9299 nivolumab, Q2049/Q2050 liposomal doxorubicin) for non-small cell lung cancer (ICD-10 C33–C34.92 range) and other solid tumors. Billing denosumab alongside these agents for NSCLC indications will result in a claim denial.

Combination with bisphosphonates is not covered. Billing denosumab alongside J1740 (ibandronate sodium/Boniva) or J3489 (zoledronic acid) as a concurrent regimen is excluded. Aetna treats step therapy as sequential, not simultaneous.

Combination with hormonal therapy for breast cancer indications is also flagged as not covered. Codes S0156 (exemestane), S0170 (anastrozole), and S0187 (tamoxifen) appear in the exclusions group when billed in combination with denosumab for these indications.

If you're billing for oncology patients who are on multiple agents, map your ICD-10 codes carefully. The combination exclusions are tied to specific diagnosis code ranges, not just drug pairs. Your billing team should check both the drug codes and the diagnosis codes before submitting.

---

Coverage Indications at a Glance

---

Aetna Denosumab Billing Guidelines and Action Items 2025

The effective date of December 20, 2025 is already past. If you haven't reviewed your workflow, do it now.

Copy Action Items

If you're managing oncology patients on multi-drug regimens and you're unsure whether your specific combination falls under the exclusion criteria, loop in your compliance officer before submitting claims. The combination exclusions are nuanced and the financial exposure on Xgeva billing is significant.

---

CPT, HCPCS, and ICD-10 Codes for Denosumab Under CPB 0804

Covered HCPCS Codes (When Medical Necessity Criteria Are Met)

Administration CPT Codes

Code	Type	Description Copy
96372	CPT	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular
96401–96450	CPT	Chemotherapy administration codes (series)

Not Covered HCPCS Codes (Combination Exclusions)

Key ICD-10-CM Diagnosis Codes

The full ICD-10-CM list under CPB 0804 includes 131 codes. The complete set is available in the full policy at app.payerpolicy.org/p/aetna/0804.

---